UTICA, NY--(Marketwired - May 9, 2013) - CONMED Corporation (NASDAQ: [ CNMD ]), a medical technology company specializing in medical devices for orthopedic and general surgery, announced today that the Company will participate in three investor conferences during the month of May as follows:

• 2013 Bank of America Merrill Lynch Health Care Conference on May 16, 2013 at 8:40 AM Pacific, at the Encore at the Wynn Hotel in Las Vegas 
  
  
• UBS Global Healthcare Conference on May 22, 2013 at 11:30 AM Eastern, at The Sheraton New York Hotel in New York
  
  
• 38^th Annual Deutsche Bank Health Care Conference on May 30, 2013 at 4:10 PM Eastern, at The Westin Boston Waterfront Hotel in Boston
  
  

Mr. Joseph J. Corasanti, President and CEO of CONMED, will discuss the Company's business. The live webcasts of CONMED's presentations will be available at [ www.conmed.com ] in the Investors section of the website and will be available for replay through June 7, 2013.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.

Forward Looking Information

Certain statements made in the presentation may constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. They will be based upon management's expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management's assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.